CONTRACT Pharmaceutical Services of Australia (CPSA) is undertaking a $1m review of plant and equipment.
Following the seamless technical transfer to its new custom built facility of 6300m2 in North Ryde, the company is meeting with local and international agents to appraise the latest state-of-the-art technology.
“The review and eventual purchase of new technology will complete phase two of the company’s relocation and expansion,” managing director, Sol Cohen said.
Cohen said the company is pleased with the new premises and the range of benefits it delivers to meet the pharmaceutical code of GMP.
“The building incorporates a suite of cutting edge features, so in order to complete our vision for a state-of-the-art production and technical facility, we are looking at purchasing the world’s best plant equipment.”
CPSA will build on its bottling and blister pack strengths, by incorporating additional line verification equipment.
“The new building features HEPA air filtration in all open product process rooms, which we anticipate will become mandatory in pharmaceutical manufacturing in the near future.
“Our review of plant equipment will ensure we are at the forefront of our industry for many years to come,” Cohen said.
CPSA clients include some of the biggest names in the pharmaceutical and healthcare industries such as Merck Sharp & Dohme, Pfizer, Hexal, Aventis, Boots and others.
For more information contact CPSA 02 9856 3500.